Key result
A concurrent diagnosis of cancer in patients hospitalized with type 2 myocardial infarction was associated with greater odds of in-hospital mortality (aOR 1.95; 95% CI 1.26-2.99; p=0.002).
Why the study?
The prevalence, clinical characteristics, and outcomes of type 2 myocardial infarction in patients with versus without cancer required investigation.
Does a concurrent diagnosis of cancer worsen in-hospital outcomes in patients presenting with type 2 myocardial infarction?
Observational (n=61,305)
Yes
Does a concurrent diagnosis of cancer worsen in-hospital outcomes in patients presenting with type 2 myocardial infarction?
Patients with cancer presenting with type 2 myocardial infarction have higher in-hospital mortality and are less likely to undergo invasive coronary angiography compared to those without cancer.
Cancer co-diagnosis signals higher type 2 MI mortality risk; hypothesis-generating for prospective risk-stratification studies.
BACKGROUND: This study aimed to investigate the prevalence, clinical characteristics and outcomes of type 2 myocardial infarction (T2AMI) in patients with versus without cancer. METHODS: All hospitalizations with a primary discharge diagnosis of T2AMI were stratified according to cancer status (secondary diagnosis of any-cancer vs cancer-free) using data from the US National Inpatient Sample (2016-2019). The primary outcome was in-hospital all-cause mortality while secondary outcomes were in-hospital major adverse cardiovascular and cerebrovascular events (MACCE). RESULTS: Among 61,305 included hospitalizations with primary diagnosis of T2AMI, 3745 (6.1%) were associated with a diagnosis of cancer. Patients with T2AMI and cancer presented more frequently with acute respiratory failure (23.2% vs 18.1%), acute pulmonary embolism (3.7% v 1.3%), major bleeding (6.8% vs 4.1%) and renal failure (51.0% vs 46.8%), compared to patients without. On adjusted analysis, diagnosis of cancer was associated with lower odds of invasive coronary angiography (aOR 0.75, 95% CI 0.60 to 0.93, p = 0.009) but greater odds of mortality (aOR 1.95, 95% C.I. 1.26-2.99 p = 0.002). Among the different types of cancer, adjusted risk of all-cause mortality was higher in patients with colorectal (aOR 4.17 95% CI 1.68-10.32, p = 0.002), lung (aOR 3.63, 95% CI 1.83-7.18, p < 0.001) and haematologic (aOR 2.48, 95% CI 1.22-5.05, p = 0.001) cancer. CONCLUSIONS: Patients with cancer presenting with T2AMI have lower odds of management with invasive diagnostic coronary angiography and have higher rates of in-hospital all-cause death. Further studies are warranted to improve overall care and outcomes of cancer patients and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Castaldi et al. (2023) conducted an observational in Type 2 myocardial infarction (n=61,305). Cancer diagnosis vs. No cancer diagnosis was evaluated on In-hospital all-cause mortality (aOR 1.95, 95% CI 1.26-2.99, p=0.002). A concurrent diagnosis of cancer in patients hospitalized with type 2 myocardial infarction was associated with greater odds of in-hospital mortality (aOR 1.95; 95% CI 1.26-2.99; p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: